within Pharmacolibrary.Drugs.ATC.M;

model M09AX10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.55,
    Cl             = 0.034499999999999996,
    adminDuration  = 600,
    adminMass      = 0.005,
    adminCount     = 1,
    Vd             = 0.137,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013333333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Risdiplam is an orally administered small molecule used for the treatment of spinal muscular atrophy (SMA). It acts as a survival motor neuron 2 (SMN2) splicing modifier, increasing production of functional SMN protein. Risdiplam is currently approved by the FDA and EMA for use in both pediatric and adult patients with SMA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers and SMA patients, after oral administration.</p><h4>References</h4><ol><li><p>Baranello, G, et al., &amp; Servais, L (2021). Risdiplam in Type 1 Spinal Muscular Atrophy. <i>The New England journal of medicine</i> 384(10) 915–923. DOI:<a href=&quot;https://doi.org/10.1056/NEJMoa2009965&quot;>10.1056/NEJMoa2009965</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33626251/&quot;>https://pubmed.ncbi.nlm.nih.gov/33626251</a></p></li><li><p>Chiriboga, CA, et al., &amp; Muntoni, F (2024). JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam. <i>Journal of neurology</i> 271(8) 4871–4884. DOI:<a href=&quot;https://doi.org/10.1007/s00415-024-12318-z&quot;>10.1007/s00415-024-12318-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38733387/&quot;>https://pubmed.ncbi.nlm.nih.gov/38733387</a></p></li><li><p>Kletzl, H, et al., &amp; Günther, A (2022). Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam. <i>British journal of clinical pharmacology</i> 88(8) 3749–3759. DOI:<a href=&quot;https://doi.org/10.1111/bcp.15319&quot;>10.1111/bcp.15319</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35301746/&quot;>https://pubmed.ncbi.nlm.nih.gov/35301746</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M09AX10;
